Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 17/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GYS1 | P13807 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2347999 | 0.85 | HCRTR1 (0.38) | HCRTR1HCRTR2KDM4EALDH1A1GAA | |
| SCHEMBL2347996 | 0.85 | HCRTR1 (0.38) | HCRTR1HCRTR2KDM4EALDH1A1GAA | |
| SCHEMBL3311920 | 0.82 | GYS1 (0.39) | HCRTR1HCRTR2KDM4EALDH1A1GYS1 | |
| SCHEMBL3311912 | 0.82 | GYS1 (0.39) | HCRTR1HCRTR2KDM4EALDH1A1GYS1 | |
| SCHEMBL3315057 | 0.81 | HCRTR1 (0.36) | HCRTR1HCRTR2KDM4EALDH1A1GAA | |
| SCHEMBL3315053 | 0.80 | HCRTR1 (0.35) | HCRTR1HCRTR2KDM4EALDH1A1GAA | |
| SCHEMBL11949290 | 0.78 | PDE4B (0.37) | HCRTR1HCRTR2KDM4EALDH1A1GAA | |
| SCHEMBL11949287 | 0.78 | ALOX5AP (0.38) | KDM4EALDH1A1HPGD | |
| SCHEMBL3314174 | 0.75 | HCRTR2 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL2355432 | 0.75 | GAA (0.39) | KDM4EALDH1A1GAAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | HCRTR1 1471/4885HCRTR2 3341/4885KDM4E 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.